European Commission Expands Tecvayli-Daratumumab to Second-Line Multiple Myeloma

Company: Johnson & Johnson · Event Type: Regulatory Approval (European Commission) · Regimen: Tecvayli + Daratumumab · Indication: Relapsed/Refractory Multiple Myeloma · Date: August 21, 2026 Summary The European Commission has expanded the approval of Johnson & Johnson’s teclistamab (Tecvayli), a BCMA-targeted bispecific antibody, in…